Senseonics (NYSE:SENS) announced today that it received CE mark for the next-generation Eversense E3 CGM system. Germantown, Maryland-based Senseonics offered a previous-generation continuous glucose monitor (CGM) with a 90-day wear time. Its next-generation Eversense E3 can be used for up to six months (180 days). Europe already had a 180-day Senseonics CGM system available (Eversense […]
Ascensia Diabetes Care
Senseonics beats The Street in Q1 following Eversense E3 launch
Senseonics (NYSE:SENS) posted first-quarter results that topped the consensus revenue forecast on Wall Street. The Germantown, Maryland-based company posted profits of $86.7 million, or 19¢ per share, on sales of $2.5 million for the three months ended March 31, 2022, for a massive bottom-line gain from losses of $249.5 million this time last year despite […]
CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022
All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week. From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings. Here are five of the biggest stories to come out […]
Study shows fewer out-of-target blood glucose levels using Ascensia’s monitoring system
Ascensia Diabetes Care announced today that a new study demonstrates reduced out-of-target blood glucose ranges with its Contour system. The company, which distributes Senseonics’ Eversense continuous glucose monitor (CGM), develops the Contour blood glucose monitoring (BGM) systems and the Contour diabetes app (CDA) for people with diabetes who are managing their blood glucose levels. According […]
Senseonics announces first Eversense E3 CGM implant in U.S.
Senseonics (NYSE:SENS) announced today that the first patient was implanted with its next-generation Eversense E3 continuous glucose monitor. Germantown, Maryland-based Senseonics, in partnership with Ascensia Diabetes Care, launched the Eversense E3 long-term implantable CGM system in the U.S. earlier this week. The system received FDA approval in February for use lasting up to six months […]
Ascensia launches Senseonics’ next-gen 180-day Eversense E3 CGM in U.S.
Ascensia Diabetes Care announced today that it launched the Senseonics (NYSE:SENS) Eversense E3 system in the U.S. The next-generation Eversense E3 continuous glucose monitoring (CGM) system, developed by Germantown, Maryland-based Senseonics, received FDA approval in February for use lasting up to six months (180 days), making it the longest-lasting CGM sensor available in the U.S. Parsippany, […]
9am.health partners with Ascensia to add blood glucose meter to diabetes toolkit
9am.health announced today that it now offers the Ascensia Diabetes Care Contour Next One and Contour Next products in its diabetes kit. Patients with type 2 diabetes and prediabetes can now add Ascensia’s Contour Next One blood glucose meter and Contour Next glucose test strips to a personalized treatment plan as part of the all-in-one […]
Senseonics wins FDA approval for next-generation Eversense 180-day CGM, provides 2022 outlook
Senseonics (NYSE:SENS) announced today that the FDA approved its next-generation continuous glucose monitor system, which lasts up to half a year. Germantown, Maryland–based Senseonics designed the Eversense E3, which includes proprietary sacrificial boronic acid (SBA) technology, to extend longevity to six months (180 days). Senseonics previously offered the system with a 90-day wear time. Data […]
Ascensia inks CGM distro, development deal with Poctech
Ascensia Diabetes Care said this week that inked a deal to co-develop and distribute continuous glucose monitoring systems with device developer Poctech. According to the terms of the deal, Ascensia will become the exclusive distributor for Poctech’s existing CGM product in 13 selected markets. Ascensia said it plans to start distributing the device in the […]
Medtronic wins CE Mark for MiniMed 670G hybrid closed-loop insulin system
Medtronic (NYSE:MDT) said today that it won CE Mark approval in the European Union for its MiniMed 670G hybrid closed-loop insulin management system for Type I diabetes patients age 7 and older. Fridley, Minn.-based Medtronic said it has clinical programs under way to back expanded indications for the device, which is designed to continuously monitor regulate […]
